Turtle Creek Wealth Advisors LLC Purchases 72 Shares of Amgen Inc. (NASDAQ:AMGN)

Turtle Creek Wealth Advisors LLC lifted its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 5.5% in the third quarter, according to its most recent filing with the SEC. The firm owned 1,379 shares of the medical research company’s stock after acquiring an additional 72 shares during the period. Turtle Creek Wealth Advisors LLC’s holdings in Amgen were worth $444,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. Capital Performance Advisors LLP bought a new position in shares of Amgen during the 3rd quarter worth approximately $25,000. Strategic Financial Concepts LLC acquired a new position in Amgen during the second quarter worth $26,000. Hershey Financial Advisers LLC bought a new position in shares of Amgen during the second quarter valued at $30,000. nVerses Capital LLC acquired a new stake in shares of Amgen during the 2nd quarter worth about $31,000. Finally, Bbjs Financial Advisors LLC acquired a new position in Amgen in the second quarter valued at about $33,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on AMGN shares. William Blair reiterated an “outperform” rating on shares of Amgen in a research note on Tuesday. StockNews.com raised Amgen from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. Sanford C. Bernstein began coverage on Amgen in a research note on Thursday, October 17th. They issued an “outperform” rating and a $380.00 target price for the company. Truist Financial lowered shares of Amgen from a “buy” rating to a “hold” rating and increased their price objective for the stock from $320.00 to $333.00 in a report on Monday, October 14th. Finally, Citigroup initiated coverage on shares of Amgen in a research note on Thursday. They issued a “neutral” rating and a $335.00 target price for the company. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, Amgen presently has an average rating of “Moderate Buy” and an average price target of $333.57.

Amgen Trading Down 4.2 %

Shares of NASDAQ AMGN traded down $12.32 during midday trading on Friday, reaching $283.61. 5,325,131 shares of the stock were exchanged, compared to its average volume of 2,453,793. Amgen Inc. has a 12 month low of $260.52 and a 12 month high of $346.85. The company has a market capitalization of $152.45 billion, a price-to-earnings ratio of 36.31, a P/E/G ratio of 2.69 and a beta of 0.60. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96. The business has a 50-day simple moving average of $320.85 and a two-hundred day simple moving average of $318.05.

Amgen (NASDAQ:AMGN) last posted its earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.11 by $0.47. The firm had revenue of $8.50 billion during the quarter, compared to analysts’ expectations of $8.50 billion. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The company’s revenue was up 23.2% on a year-over-year basis. During the same period in the previous year, the firm earned $4.96 earnings per share. As a group, equities research analysts expect that Amgen Inc. will post 19.51 EPS for the current year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 9th. Stockholders of record on Monday, November 18th will be given a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a dividend yield of 3.17%. The ex-dividend date of this dividend is Monday, November 18th. Amgen’s dividend payout ratio is 115.24%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.